InMed Pharmaceuticals Inc. operates as a pharmaceutical drug development company in the United States. The company researches and develops cannabinoid-based pharmaceuticals products. Its product candidates include INM-901 for Alzheimer's disease, INM-089 for dry age-related macular degeneration, and INM-755, a cannabin…
| Periodo | 2027-02 |
|---|---|
| Real | — |
| Estimado | — |
| Sorpresa | — |
| Métrica | MTRI | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | — | 58.3% | — |
| Operating Margin | — | -31.5% | — |
| Net Margin | — | -30.9% | — |
| FCF Margin | — | -10.6% | — |
| ROE | -1168.4% | -36.3% | -1132.2% |
| ROA | -414.5% | -29.8% | -384.7% |
| Current Ratio | 1.37 | 2.68 | -1.31 |
| Debt / Equity | — | 0.28 | — |
| Tendencia (Piotroski) | FY26 | FY25 |
|---|---|---|
| ✗Rentabilidad sobre activos positiva | -414.5% | — |
| ✗Flujo de caja operativo positivo | −$9M | −$8M |
| ✗Rentabilidad sobre activos al alza | -414.5% | -52.4% |
| ✓Caja operativa/activos supera al ROA | -285.3% | ROA -414.5% |
| –Menos deuda a largo plazo | — | — |
| ✗Mejor liquidez (ratio corriente) | 1.37 | 6.99 |
| ✗Sin aumentar el nº de acciones | 4M | 1M |
| ✗Margen bruto al alza | — | 34.5% |
| ✗Rotación de activos al alza | — | 0.32 |
InMed Pharmaceuticals Inc. cotiza a 18.60 USD y tiene una capitalización bursátil de $1.1B. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud